Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
The MEIP news page on Stock Titan provides an organized view of public announcements and regulatory disclosures related to MEI Pharma, Inc. and its transition to Lite Strategy, Inc. These items trace the company’s path from a clinical-stage oncology business with a portfolio of cancer drug candidates to an enterprise emphasizing a Litecoin-focused digital asset treasury strategy.
Earlier news releases describe MEI Pharma’s work as a pharmaceutical company with drug candidates such as voruciclib and ME-344, along with updates on cash position, research and development spending, and the evaluation of strategic alternatives. These reports document the company’s efforts to preserve cash, consider out-licensing and merger and acquisition options, and adjust its workforce and clinical programs while seeking to maximize asset value for stockholders.
More recent articles highlight a major strategic shift: the launch of a Litecoin treasury initiative, a large private placement to fund this strategy, and the acquisition of a substantial Litecoin position. The company’s news also details the appointment of digital asset advisors, board changes linked to its treasury focus, and the formal rebranding to Lite Strategy, Inc. with a new NASDAQ ticker symbol, LITS.
Investors and researchers using this page can follow how MEI Pharma’s oncology-focused narrative evolved into a digital asset treasury story, including key milestones such as the private placement, Litecoin acquisitions, and the corporate name and ticker change. For ongoing developments after the symbol transition, users should also review news associated with Lite Strategy, Inc. under its current trading symbol.
MEI Pharma (NASDAQ: MEIP) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference 2022. The company will present a business update available for on-demand listening starting September 12, 2022, at 7:00 a.m. Eastern Time. The presentation will be accessible through the Investors section on the MEI Pharma website and archived for 90 days. MEI Pharma focuses on advancing cancer therapies, with candidates like zandelisib undergoing clinical trials for FDA marketing approvals.
MEI Pharma, Inc. (NASDAQ: MEIP) has granted inducement stock options totaling 64,000 shares to two new employees, aligning with Nasdaq Listing Rule 5635(c)(4). The options, priced at $0.51 per share, mirror the company's stock closing price on the grant date. These options are part of the 2021 Inducement Grant Equity Compensation Plan and are set to vest over time, beginning with 25% after one year, followed by monthly vesting for the next 36 months. MEI Pharma focuses on developing cancer therapies, including its clinical-stage candidate zandelisib.
MEI Pharma, Inc. (NASDAQ: MEIP) will announce its fiscal year-end 2022 financial results on September 8, 2022, after market close. A conference call will follow at 5:00 p.m. ET to provide a corporate overview and updates. Investors can join via a dial-in or access a live webcast through the company's website. MEI Pharma focuses on developing therapies for cancer, with ongoing clinical trials for zandelisib and other drug candidates aimed at addressing unmet medical needs. For further details, visit www.meipharma.com.
MEI Pharma, Inc. (NASDAQ: MEIP) has granted inducement stock options for 18,000 shares to a new employee, aligning with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.48 per share, matching the stock's closing price on the grant date. Vested shares will be released over a 40-month schedule, with a 10-year term. MEI Pharma is focused on developing cancer therapies, including zandelisib, which is in clinical trials aimed at securing FDA marketing approval.
MEI Pharma (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. have published Phase 1b clinical study results for zandelisib, a PI3Kδ inhibitor, in The Lancet Oncology. The study showed that an intermittent dosing schedule of zandelisib resulted in a lower risk of significant adverse events than a continuous regimen, without sacrificing efficacy. Out of 97 patients evaluated, the intermittent group exhibited a 20% incidence of Grade 3 or worse adverse events compared to 45% in the continuous group. These results support further Phase 2 and Phase 3 studies for zandelisib in patients with B-cell malignancies.
MEI Pharma, Inc. (NASDAQ: MEIP) announced a grant of inducement stock options totaling 65,000 shares to two new employees, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.60 per share, equivalent to the closing price on the grant date. These options are part of the 2021 Inducement Grant Equity Compensation Plan and will vest over a 10-year term. MEI Pharma focuses on developing new cancer therapies, notably zandelisib, currently undergoing clinical trials aimed at marketing approval from regulatory authorities.
MEI Pharma, Inc. (NASDAQ: MEIP) has appointed Anne Frese as chief people officer, effective immediately. Frese brings over 30 years of human resources experience from various industries, her most recent position being chief human resources officer at Vyripharm Enterprises. CEO Daniel P. Gold expressed confidence in Frese's ability to enhance team development and align with MEI's mission to improve patient lives. This strategic move aims to strengthen MEI’s organizational culture as it advances its cancer therapies, including zandelisib, currently undergoing clinical trials.
MEI Pharma announced promising data from the zandelisib clinical development program presented at the 2022 European Hematology Association Hybrid Congress. The Phase 2 TIDAL study reported a 70.3% objective response rate and a 35.2% complete response rate in patients with relapsed or refractory follicular lymphoma. Notably, 87.5% of responses occurred within the first two therapy cycles. Adverse events led to a 9.9% discontinuation rate, primarily consisting of Grade 3 AEs. The study aims to continue assessing zandelisib's safety and efficacy as enrollment progresses in additional cohorts.
MEI Pharma and Kyowa Kirin presented data from the ongoing Phase 2 TIDAL study on zandelisib at the ASCO 2022 Annual Meeting. The study showed a 70.3% objective response rate and a 35.2% complete response rate among patients with relapsed or refractory follicular lymphoma. Notably, 87.5% of responses occurred within the first two cycles of therapy. Safety data indicated that 9.9% of patients discontinued for drug-related adverse events, with 83% reporting Grade 3 adverse events primarily in initial treatment cycles. The results support the continued development of zandelisib, particularly in the Phase 3 COASTAL study.
MEI Pharma (NASDAQ: MEIP) has granted stock options for 40,000 shares to a new employee as an inducement for employment. The exercise price is $0.48 per share, equal to the closing stock price on the grant date. Approved by the Compensation Committee, the options will vest over a period of four years, with 25% vesting on the first anniversary and the remaining vesting monthly. This action aligns with the company’s 2021 Inducement Grant Equity Compensation Plan.